In addition, the beneficial effects on dyslipidemia, hepatic lipid accumulation, steatosis, NAS, and down regulation of inflammatory (IL-8, MCP-1, TNF-α) and fibrogenic (TGF-β, Col1a1, α-sma) target genes were recorded, supporting a positive outcome of the combination of diet change and vitE supplementation in NASH management [20]. The gene discussed is ACTA1; the disease is metabolic syndrome.